Dysport
(AbobotulinumtoxinA)ApprovedBiologic
This medication is a neurotoxin injection that blocks nerve signals to reduce uncontrollable muscle tightening and spasms. It's used to treat conditions like cervical dystonia (severe neck muscle contractions), reduce wrinkles between the eyebrows, and relieve muscle stiffness in the arms and legs.[2] Dysport is currently approved and in use across 5 indications[4].[1]
Dysport is one of 53 biologic programs targeting Headache. It is currently in Approved.
5
Indications
15
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
64 competitors in Shoulder Pain
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Savella
AbbVieApproved
Prostigmin
Merck & Co.Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Medrol
PfizerApproved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Kenalog
BBassett Healthcare
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Dysport
GGalderma R&D
Approved
Marcaine
IInnocoll
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Botulinum Toxin3 trials
Safety and Efficacy2 trials
Glabellar Lines1 trial
7 more indications
Efficacy and Safety1 trial
Adolescent Idiopathic Scoliosis1 trial
Shoulder pain1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Dysport drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for AbobotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Modality
- Biologic[3]
- Highest Phase
- Approved[1]
- Company
- GGalderma R&D